Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 94 clinical trials
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients.

  • 12 views
  • 28 Feb, 2022
  • 2 locations
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling

  • 0 views
  • 23 Feb, 2021
  • 1 location
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.

metastatic melanoma
immunologic adjuvant
serum pregnancy test
advanced melanoma
immunomodulators
  • 0 views
  • 27 Sep, 2021
  • 1 location
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

This research study is studying a new type of personalized neoantigen vaccine (NeoVax) plus Montanide in combination with Ipilimumab (Yervoy) and Nivolumab (Opdivo) as a possible treatment for melanoma. The drugs involved in this study are: Personalized Neoantigen Vaccine Poly-ICLC (Hiltonol) Montanide Ipilimumab (Yervoy) Nivolumab (Opdivo)

vitiligo
yervoy
alopecia
ipilimumab
vaccination
  • 0 views
  • 19 Nov, 2021
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

This open-label phase II trial studies how well olaparib in combination with pembrolizumab works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and …

  • 0 views
  • 14 May, 2021
  • 1 location
Safety Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety, tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and urothelial carcinoma

  • 2 views
  • 31 Jul, 2021
  • 1 location
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

The main purpose of this study is to Evaluate the Efficacy and Safety of the combination of HL-085 and Vemurafenib in Advanced Melanoma Patients with BRAF V600E/K Mutation. This study includes

advanced melanoma
measurable disease
BRAF
vemurafenib
platelet count
  • 0 views
  • 29 Apr, 2022
  • 1 location
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-PD1 therapy with or without concomitant anti-CTLA4 therapy. Patients will receive treatment with nivolumab 480 mg intravenously every 4 weeks and axitinib 5 mg twice daily by …

  • 0 views
  • 30 Apr, 2022
  • 1 location
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma. The primary objective of the study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. The …

metastatic melanoma
advanced melanoma
nivolumab
  • 0 views
  • 18 May, 2022
  • 25 locations
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (ATLAS-IT-05)

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either

  • 0 views
  • 18 May, 2022
  • 2 locations